About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Subscribe To Our Newsletter & Stay Updated
